Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DDX43
REST API REST API
Homo sapiens
DDX43 is differentially expressed in 138 experiments: 57 organism parts: testis, trigeminal ganglion, ... (55 more);, 61 disease states: normal, choriocarcinoma, ... (59 more);, 35 cell types 325 cell lines 18 compound treatments and 56 other conditions.
Synonyms DKFZp434H2114, CT13, HAGE
Orthologs F1NQ09_CHICK (Gallus gallus)   ddx43 (Danio rerio)   DBP2 (Saccharomyces cerevisiae)   Ddx43 (Mus musculus)   DDX43 (Bos taurus)   F6SZR5_CIOIN (Ciona intestinalis)   CG7878 (Drosophila melanogaster)   ddx43 (Xenopus laevis)   DDX43 (Canis familiaris)   (Compare orthologs)
InterPro Term KH_type_1_subgr, KH_type_2, KH_type_1, DNA/RNA_helicase_DEAD/DEAH_N, RNA_helicase_DEAD_Q_motif, KH, Helicase_C, DEAD-like_helicase
Gene Ontology Term intracellular, ATP-dependent RNA helicase activity, ATP-dependent helicase activity, nucleic acid binding, ATP binding, nucleotide binding, hydrolase activity, RNA binding, helicase activity
UniProt Accession Q9NXZ2, B4E0C8
Search EB-eye ENSG00000080007
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (26 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
T84
2
E-MTAB-37, E-GEOD-1474
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
H441
2
E-GEOD-16194, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
319 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-MTAB-25, E-GEOD-20033, E-GEOD-3920, ... (19 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-3982, E-GEOD-8286
eosinophil
1
E-GEOD-3982
HLA-DR negative T-cell
1
E-GEOD-6338
naive T cell
1
E-GEOD-1460
monocyte
1
E-GEOD-8286
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
29 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2442, E-MTAB-62, E-GEOD-14895, ... (16 experiments)

Factor Value U/D Experiments
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-GEOD-7307
normal
1
2
E-TABM-276, E-GEOD-3167, E-GEOD-2724
uterine fibroid
1
E-GEOD-2724
treated malaria, natural infection Cameroon
1
E-GEOD-5418
colon carcinoma
1
E-MTAB-62
55 more value(s).


Compound treatment

studied in E-MEXP-1269, E-TABM-782, E-GEOD-2292, E-TABM-127, E-MEXP-1958, ... (11 experiments)

Factor Value U/D Experiments
none
3
E-MEXP-1958, E-TABM-782, E-MEXP-1269
AMP
1
E-MEXP-2285
cigarette smoke
1
1
E-TABM-127
4OH-tamoxifen
1
E-GEOD-2292
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
estradiol
1
E-GEOD-20081
12 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
adrenal gland; kidney
1
E-GEOD-5851


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-3494, E-GEOD-2724, E-TABM-601

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-GEOD-9764, E-MEXP-1103

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-MEXP-1648, E-TABM-15, ... (25 experiments)

Infection
studied in E-GEOD-12254, E-GEOD-17400

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19246

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-MEXP-548

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sex
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-8052, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.335 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM